+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pancreatic Cancer - Epidemiology Forecast to 2029

  • PDF Icon

    Report

  • 46 Pages
  • November 2020
  • Region: Global
  • GlobalData
  • ID: 5212225
Summary

Pancreatic cancer (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C25) is the seventh leading cause of cancer deaths worldwide. Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA and grow uncontrollably. These accumulating cells form a tumor. Untreated pancreatic cancer spreads to nearby organs and blood vessels. PDAC or pancreatic exocrine cancer is the most common type of pancreatic cancer and begins in the cells that line the ducts of the pancreas. PDAC is an aggressive form of pancreatic cancer where approximately 60-80% of patients already have distant metastasis at presentation.

The publisher's epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, considering the significant relationship between age and incidence. The publisher's epidemiologists applied country-specific incidence rates of pancreatic cancer, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of PDAC cases. In 2019, the 8MM had 178,128 diagnosed incident cases of PDAC. This is expected to increase to 224,769 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 2.62%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the five-year diagnosed prevalent cases of PDAC will increase from 113,292 cases in 2019 to 140,914 cases in 2029, at an AGR of 2.44%. The early diagnosis and development of more effective therapies, particularly for elderly patients, would improve survival from PDAC.

Scope

  • Pancreatic Cancer Epidemiology Report provides an overview of the risk factors and global trends of pancreatic ductal adenocarcinoma (PDAC) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
  • This report also includes a 10-year epidemiological forecast for the following segmentations across the 8MM: diagnosed incident cases of pancreatic cancer and PDAC; PDAC segmented by sex and age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older); diagnosed five-year prevalent cases PDAC; diagnosed incident cases of PDAC by cancer staging; and diagnosed incident cases of PDAC by biomarkers.
  • The Pancreatic Cancer Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The PDAC Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer and PDAC market.
  • Quantify patient populations in the global PDAC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the PDAC cancer stages that present the best opportunities for PDAC therapeutics in each of the markets covered.
  • Understand magnitude of PDAC market by biomarkers.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pancreatic Cancer: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases of Pancreatic Cancer and PDAC
3.4.4 Diagnosed Incident Cases of PDAC by Stages
3.4.5 Diagnosed Incident Cases of PDAC by Familial PDAC by Germline Mutation
3.4.6 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Fusion Mutation
3.4.7 Diagnosed Incident Cases of PDAC by PD-L1 Expression
3.4.8 Five-Year Diagnosed Prevalent Cases of PDAC
3.5 Epidemiological Forecast for Pancreatic Cancer, 2019-2029
3.5.1 Diagnosed Incident Cases of Pancreatic Cancer
3.5.2 Diagnosed Incident Cases of PDAC
3.5.3 Sex-Specific Diagnosed Incident Cases of PDAC
3.5.4 Age-Specific Diagnosed Incident Cases of PDAC
3.5.5 Diagnosed Incident Cases of PDAC by Stage at Diagnosis
3.5.6 Diagnosed Incident Cases of Familial PDAC by Germline Mutations
3.5.7 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Mutations
3.5.8 Diagnosed Incident Cases of PDAC by PD-L1 Expression
3.5.9 Five-Year Diagnosed Prevalent Cases of PDAC
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 COVID-19 Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Publisher
4.4 Contact
4.5 Disclaimer
List of Tables
Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for PDAC
List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of PDAC, Both Sexes, Ages =18 Years, N, 2019 and 2029
Figure 2: 8MM, Diagnosed Incidence of PDAC, Men, Ages =18 Years, 2009-2029, Cases Per 100,000 Population
Figure 3: 8MM, Diagnosed Incidence of PDAC, Women, Ages =18 Years, 2009-2029, Cases Per 100,000 Population
Figure 4: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of Pancreatic Cancer and PDAC
Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of PDAC by Stage at Diagnosis
Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Familial PDAC by Germline Mutation
Figure 7: 8MM, Sources Used to Forecast of PDAC by KRAS and NTRK Gene Fusion Mutation
Figure 8: 8MM, Sources Used to Forecast the PD-L1 Expression of PDAC
Figure 9: 8MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of PDAC
Figure 10: 8MM, Diagnosed Incident Cases of Pancreatic Cancer, Both Sexes, Ages =18 Years, N, 2019
Figure 11: 8MM, Diagnosed Incident Cases of PDAC, Both Sexes, Ages =18 Years, N, 2019
Figure 12: 8MM, Diagnosed Incident Cases of PDAC, by Sex, Ages =18 Years, N, 2019
Figure 13: 8MM, Diagnosed Incident Cases of PDAC by Age, Both Sexes, N, 2019
Figure 14: 8MM, Diagnosed Incident Cases of PDAC by Stage at Diagnosis, Ages =18 Years, Both Sexes, N, 2019
Figure 15: 8MM, Diagnosed Incident Cases of Familial PDAC by Germline Mutations, Ages =18 Years, Both Sexes, N, 2019
Figure 16: 8MM, Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Fusion Mutations, Ages =18 Years, Both Sexes, N, 2019
Figure 17: 8MM, Diagnosed Incident Cases of PDAC by PD-L1 Expression, Ages =18 Years, Both Sexes, N, 2019
Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of PDAC, Ages =18 Years, Both Sexes, N, 2019